Articles related to AMYOTROPHIC LATERAL SCLEROSIS (ALS)

This recent development regarding survival rates in the study underscores the complexity and challenges in developing effective treatments for ALS.

The FDA’s recent concerns about NurOwn’s efficacy and manufacturing consistency could have far-reaching implications for the future of ALS treatment. Stay updated as the agency’s final decision is expected in December.

Discover how a study from USC reveals that the most common genetic cause of ALS and FTD may have its roots in embryonic development, offering new avenues for early diagnosis and treatment.

Scientists at the Harvard T.H. Chan School of Public Health are looking at the role of alpha-linolenic acid in ALS management, as their research links high blood levels of this omega-3 fatty acid to slower disease progression and longer survival in patients.

Unraveling the ALS Treatment Landscape: An Insightful Webinar Pharmacists, step into an enlightening discussion about the ALS treatment landscape on June 14th from 2:00 – 3:00 PM EST. Unearth key insights from AMCP’s Market Insights Roundtable and explore strategies to navigate patient access barriers, ultimately enriching ALS patients’ quality of life. Firstly, the webinar presents a golden opportunity for pharmacists to deepen their understanding of Amyotrophic Lateral Sclerosis (ALS), a rapidly progressing neurodegenerative disease. Our distinguished speakers will guide you through the current and evolving ALS treatment landscape, emphasizing the differences between clinical trial environments and real-life experiences. Further along, you’ll gain invaluable insights into the patient journey and the burden associated with ALS. In highlighting the current access barriers that patients face, the webinar focuses on a health plan’s concerted effort to mitigate these hurdles, providing valuable lessons for all healthcare stakeholders. Lastly, the importance of collaboration in the decision-making process to minimize access to care barriers will be underscored. With panelists like Ryan Haumschild, Director of Pharmacy at Emory Healthcare and Winship Cancer Institute, and Ryan Bitton, Senior Director of Pharmacy Services at Health Plan of Nevada, this is a conversation you won’t want to miss. Join us […]

Researchers presented findings from the AB10015 Phase 2/3 clinical trial, demonstrating that masitinib, an oral add-on therapy to Rilutek, offers significant benefits for patients with mild to moderate amyotrophic lateral sclerosis (ALS). Although the entire study population did not experience improved survival with masitinib, patients with moderate ALS who received masitinib in addition to Rilutek had significantly longer survival compared to those who received a placebo. The combined treatment also slowed disease progression, improved lung function, and enhanced quality of life in these patients. Masitinib works by blocking specific tyrosine kinase enzymes that regulate immune cell activity and inflammation, aiming to slow disease progression and alleviate symptoms. The analysis focused on normally progressing participants with moderate ALS at the study’s start, and in this subgroup, masitinib combined with Rilutek significantly slowed disease progression by 42% compared to Rilutek alone. Additionally, patients with moderate ALS experienced a median survival of 69 months with masitinib, representing a 44% reduction in mortality risk compared to placebo-treated patients. The combination therapy also showed positive effects on quality of life and lung function in patients progressing normally. These findings suggest that initiating masitinib at an earlier stage of the disease could lead to substantial reductions […]